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Abstract 
Patients who have experienced adverse drug reactions (ADRs) can show some psychological problems 
both pre-existing than consequently the reactions. Anxiety, depression, somatization, as well as a minor 
capability of expressing emotions, have been demonstrated in some of these subjects. Nevertheless, a 
negative expectation toward a new drug administration related to some nocebo reactions can 
complicate the evaluation of these patients. This study aims to investigate the link between the nocebo 
effect and emotional functioning in ADRs patients to better understanding the psychological 
mechanisms involved in this phenomenon. Therefore, patients who have manifested or not (non 
responders) a nocebo reaction following the administration of an inert substance (placebo) have been 
compared. One hundred twenty patients (N = 30 with nocebo reactions; N = 90 non responders) 
completed the Difficulties in Emotion Regulation Scale, Emotion Regulation Questionnaire, and Toronto 
Alexithymia Scale-20. ADRs patients with nocebo reactions showed: 1) higher level of Cognitive 
Reappraisal than non responders; 2) associations between higher level of emotion dysregulation and 
not immediate drug reactions; 3) associations between higher level of alexithymia, Expressive 
Suppression and more frequent access to healthcare services; 4) alexithymia and Expressive 
Suppression as predictors of more frequent access to healthcare services, evident in 35% of the sample. 
The clarification of some psychological mechanisms involved in the nocebo effect is a basic 
prerequisite to better understand and manage these patients. 
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1. Introduction 
Adverse drug reactions (ADRs) are very common in clinical practice, and women are involved 
in 57–70% of cases (Rademaker, 2001). These patients show various and polymorphous 
symptoms (e.g., cutaneous symptoms, respiratory symptoms, systemic symptoms), not 
infrequently associated with psychological distress (De Pasquale et al., 2012). Their clinical 
history is characterized by anxiety or depression, but it is unclear if psychological factors are 
antecedents or are the consequence of this particular kind of disease (Berrino et al., 2005).  
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According to Hauser and colleagues (Häuser, Hansen, & Enck, 2012), ADRs can be related to 
the nocebo effect that occurs when patients suffering from several illnesses exhibit troublesome 
symptoms after the administration of inert substances. This is an opposite phenomenon to the 
placebo effect (i.e., a substance without medical effects which benefits the health status because 
of the patient's belief that the substance is effective) (Požgain, Požgain, & Degmečić, 2014). The 
nocebo phenomenon is influenced by several factors, as patient’s expectation, previous 
experience, setting, appearance of the drug, and psychological features as anxiety, depression, 
and a tendency toward somatization (Berrino et al., 2005; Bizzi, Voltolini, Fiaschi, & Cavanna, 
2019; Hermes, Hein, & Henz, 2006; Liccardi et al., 2004; Rief, Hofmann, & Nestoriuc, 2008; 
Wells & Kaptchuk, 2012). In particular, depression is associated with a pessimistic perception 
of self or events and in the context of receiving a new drug, the expectation is that the 
medication is not likely to do anything positive and it will make things worse. Anxiety is linked 
with a hypervigilant reaction for harmful dangerous situations and may anticipate harm from a 
pill and the somatization (Colloca & Benedetti, 2007).  
Studies on the nocebo effect mainly focus on biological mechanisms (Benedetti et al., 2007; 
Colloca & Miller, 2011; Lombardi, Gargioni, Canonica, & Passalacqua, 2008) rather than on 
psychological features as emotional functioning. However, this would have direct implications 
for well-being of these patients (Balzarotti, Biassoni, Prunas, & Velotti, 2016; Gross & John, 
2003), considering that an inability to cope with negative emotions is considered a central feature 
of clinical outcome (Aldao, Nolen-Hoeksema, & Schweizer, 2010); a difficulty in regulating 
emotions is linked with psychosomatic symptoms (Lundh, Wikström, & Westerlund, 2001); 
alexithymic features are linked with psychosomatic disease as well as to a general deficit in the 
ability to tolerate negative emotions and to connect them to physical sensations (Subic-Wrana, 
Beutel, Knebel, & Lane, 2010). 
Therefore, an emotion regulation perspective is adopted in the study considering emotion 
dysregulation, maladaptive use of emotion regulation strategies, and alexithymia features. 
Specifically, emotion dysregulation is defined here as a multidimensional construct 
encompassing maladaptive ways of responding to emotional distress, including: a lack of 
awareness, understanding, and acceptance of emotions; an unwillingness to experience 
emotional distress as part of pursuing desired goals; difficulties controlling behaviors in the face 
of emotional distress; and deficits in the modulation of emotional arousal through effective 
emotion regulation strategies (Gratz & Roemer, 2004). Expressive Suppression (the opposite to 
Cognitive Reappraisal) is meant here as maladaptive emotion regulation strategy that attempts 
to hide, reduce or inhibit emotion regulation strategies on a verbal and non-verbal level, without 
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reducing the subjective and physiological experience of negative emotions that continue 
unresolved (Gross, 1998). Alexithymia is meant as difficulties identifying feelings, 
communicating feelings to other people and externally oriented thinking (Bagby, Parker, 
&Taylor, 1994).  
Reviewing the literature on multifaceted role played by emotions in ADRs patients, Patriarca 
and colleagues (1991) found a tendency to suppress the expression of affects using the 
Rorschach’s test in patients with multiple drug intolerance. The presence of a smaller quantity 
of energy led to a minor capability of expression emotions and a major expression of depressive 
feelings, probably for an expressive inhibition and an impossibility to mental elaboration. 
Additionally, De Pasquale et al. (2012) found in these patients an inability to use verbal language 
to describe feelings, an impoverished fantasy life, and a poor communicative style. Alexithymia 
features were also found in patients with other types of allergic diseases, like bronchial asthma 
(Baiardini et al., 2011; Baiardini, Sicuro, Balbi, Canonica, & Braido, 2015). However, studies on 
emotional functioning in ADRs patients with nocebo effects are lacking.  
Starting from these considerations whereby an emotional inhibition is common in patients with 
multiple drug intolerance (De Pasquale et al., 2012; Patriarca et al., 1991) and a general deficit 
to regulate emotions connecting with physical sensations may worsen the outcome of the 
patients (Colloca & Benedetti, 2007; Rief et al., 2008), it is hypothesized to find emotional 
problems mainly in ADRs patients that show nocebo reactions. In this way, two groups of 
subjects that in an identical diagnostic context have manifested or not (non responders) a 
nocebo effect administrating a placebo are compared. The first study’s objective concerns to 
test the emotional functioning in patients with nocebo reactions comparing with non 
responders; secondly, the link between clinical anamnestic data (i.e., number of drug reactions, 
time of reactions, severity of reactions, access to healthcare services) and emotional problems 
in these patients is investigated to better understand the existence of factors favoring. 
 
2. Materials and methods 
2.1 Participants 
Among all the patients with a clinical history of ADR, 120 were recruited consecutively from 
the Allergy Unit of the San Martino IST University Hospital (Genoa, Italy) in the first months 
of 2016 because they needed to be submitted to challenge test. The mean age of participants is 
46.59 (SD = 15.50), 82% are females and 21% have awarded a degree. The anamnestic clinical 
data concerning the previous reactions are shown in Table 1.  
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Seventy-six percent of patients have a history of multiple ADR with more than one category of 
drugs involved and 51% have experienced immediate drug reactions. Thirty-one% of the total 
have experienced mild reactions, while most of them have moderate-severe reactions, and 52% 
referred to Emergency Health Care structures (Medical Ward or Hospital Emergency 
Department). 
Table 1. Clinical data of patients with ADRs 
Clinical data of  patients  Percentages % 
Number of  drug reactions    1 = 24% 
>1 = 76% 
Time of  reactions Immediate = 51% 
Not immediate = 30 % 
Not specified = 19% 
Severity of  reactions Mild = 31% 
Moderate - Severe = 59% 
Not specified = 10% 
Access to healthcare services Yes = 52% 
No = 48% 
Of the total participants, N = 30 (25%) showed nocebo reactions to oral placebo while N = 90 
were non responders. The demographic characteristic of the sample is shown in Table 2. The 
only significant difference is about the age (t(118) = 3.22, p = .002), showing older age in patients 
with nocebo effect than non responders. 
Table 2. Demographic characteristic of ADRs patient with nocebo effects and no responders 
  Patients with 
nocebo effect  
(N = 30) 
Non responders 
 
(N = 90) 
Statistics 
Gender  Female 28.6% 71.4% chi2(1) = 3.64, p = .057 
 Male 9.1% 90.9%  
Age mean (SD)  54.20 (12.77) 44.06 (15.56) t(118) = 3.22, p = .002** 
Educational 
level 
Non-graduates  23.4% 76.6% chi2(1) = .774, p = .379 
 Graduates 32% 68%  
Note: *** p < .001; ** = p < .01; * = p < .05 
In almost all cases of patients with nocebo effect the reactions were mild and most of the 
symptoms were subjective with a few cases of objective reactions: 27% skin symptoms (itching, 
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burning sensation, paresthesia), 33% neurological symptoms (agitation, tremors, dizziness, 
headache), 20% gastrointestinal symptoms (nausea, abdominal pain, diarrhea), 10% respiratory 
symptoms (dyspnea, laryngeal obstruction sensation), 10% cardiovascular symptoms (hypo or 
hypertension, tachycardia). 
2.2 Measures 
The Difficulties in Emotion Regulation Scale (DERS; Gratz & Roemer, 2004) is a widespread self-
report measure of emotion dysregulation and confirmed its good psychometric properties and 
its construct and predictive validity in the Italian adaptation of the scale (Giromini, Velotti, de 
Campora, Bonalume, & Zavattini, 2012). The DERS assesses difficulties in six clinically relevant 
dimensions of emotion regulation through 36 items rated on a 1 to 5 Likert (from “almost 
never” to “almost always”). The scales were the following: No acceptance of Emotional 
Response (Nonacceptance), Difficulties Engaging in Goal-Directed Behavior (Goal), Impulse 
Control Difficulties (Impulse), Lack of Emotional Awareness (Awareness), Limited Access to 
Emotion Regulation Strategies (Strategies), and Lack of Emotional Clarity (Clarity). Greater 
scores on any of these scales are indicative of greater difficulties in each emotion regulation 
dimension. In our study is reported internal consistency of .93.  
The Emotion Regulation Questionnaire (ERQ; Gross & John, 2003), a 10-item self-report 
questionnaire that assesses the use of an adaptive strategy of emotion regulation, the Cognitive 
Reappraisal (6 items), and a maladaptive strategy of emotion regulation, the Expressive 
Suppression (4 items). The items were rated on a 7-point-Likert scale from “strongly disagree” 
to “strongly agree”. The Italian version of the ERQ (Balzarotti, John, & Gross, 2010) has 
demonstrated good internal consistency and two-month test-retest reliability (.67 for 
Reappraisal and .71 for Suppression), comparable to that of the original English version of the 
ERQ. In our study is reported internal consistency of .83 for Reappraisal and of .74 for 
Suppression.  
The Toronto Alexithymia Scale-20 (TAS-20; Bagby et al., 1994) was administered in its Italian 
adaptation (Bressi et al., 1996) to measure individuals' levels of alexithymia. The TAS-20 is a 
self-report questionnaire comprising 20 items on a 5-point Likert scale. A total alexithymia score 
is obtained by summing scores on three dimensions: Difficulty in Identifying Feelings (DIF), 
Difficulty in Describing Feelings (DDF), and External Oriented Thinking (POE). In our study 
is reported internal consistency of .75. 
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2.3 Procedure 
All participants voluntarily took part in the study after the first medical visit where the clinician 
explained the meaning of the study, providing written informed consent. After the collection of 
anamnestic data, including the description of symptoms and circumstances of the reaction, the 
patients were submitted to an allergological workup, comprehensive of oral gradual challenge 
test for one or more drugs. Standard procedure, beginning with a first day of placebo 
administration (four doses of inert substance at 30’ interval, followed by one hour observation 
of patient) was performed by an experienced allergist together with a nurse in the hospital setting 
where emergency equipment was available (Bavbek, Pasaoglu, Canat, Sagduyu, & Misirligil, 
2006). During the first day of the oral test, all patients compiled three questionnaires of their 
emotional functioning.  
The oral challenge with placebo was administered according to the recommendations of the 
ENDA group of the European Academy of Allergy and Clinical Immunology. The 
psychological measures complied with the official directions established by the American 
Psychological Association and the Italian Association of Psychology. Since all tests were 
performed for diagnostic purposes, ethical committee approval was not required. 
2.4 Data analytic plan 
The results are analyzed using the Statistical Package for Social Science (SPSS, Version 21.0; 
IBM Corp., Armonk, NY, USA). Descriptive statistics are computed for all study variables and 
all sociodemographic information available. Parametric tests, as Independent sample t-test, Chi-
square, ANOVA are used to examine group differences. Point biserial correlations are used to 
test the association between nominal (clinical anamnestic data of ADRs patients) and 
quantitative variables (DERS, ERQ, TAS-20 scores). Besides, logistic regression analysis is used 
to test the prediction power of emotion regulation problems on clinical anamnestic features of 
the ADR in nocebo patients. The level of significance for all analyses was p < .05.  
 
3. Results 
Table 3 shows scores derived from DERS, ERQ and TAS-20. All of these dependent variables 
display adequate distributional characteristics, and there is no substantial skewness or kurtosis. 
Comparing patients with nocebo effect (N = 30) with non responders (N = 90), the only 
significant difference is found on ERQ respect to Cognitive Reappraisal. Higher level of 
Cognitive Reappraisal in patients with nocebo effect (M = 34.20, SD = 6.89) than non 
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responders (M = 29.82, SD = 7.45, t(118) = 2.84, p = .005) is found. To control age differences 
on these scores, ANOVA is applied; findings show significant effects for age (F(1, 120) = 2.34, 
p = .015, eta2 = .20), but no for group (F(1, 120) = 1.41, p = .174, eta2 = .13). Significant 
interaction is not found. 
Table 3. DERS, ERQ and TAS-20 scores in ADRs patients with nocebo effects and in non 
responders 
Measures  Nocebo effects 
M (SD) 
Non responders 
M (SD) 
t(118) 
 
DERS NON ACCEPTANCE 12.27 (5.13) 12.49 (4.99) -.21 
 GOAL 13.10 (3.27) 13.29 (3.60) -.25 
 IMPULSE 11.43 (2.86) 11.61 (3.14) -.27 
 AWARENESS 23.43 (4.41) 22.67 (3.55) .96 
 STRATEGY 16.87 (5.21) 15.81 (4.01) 1.15 
 CLARITY 12.80 (1.19) 13.20 (1.36) -1.44 
 DERS Total 89.90 (15.29) 89.07 (13.03) .29 
ERQ CR 34.20 (6.89) 29.82 (7.45) 2.84* 
 ES 11.77 (5.49) 11.81 (5.53) -.04  
TAS-20 DIF 13.00 (5.46) 13.29 (5.23) -.26 
 DDF 13.00 (4.50) 12.42 (3.25) .76 
 POE 27.07 (3.61) 26.82 (3.73) .31  
 TAS-20 Total 106.60 (14.43) 104.32 (14.98) .73 
Note: DERS: Difficulties in Emotion Regulation Scale; ERQ: Emotion Regulation Questionnaire; TAS-
20: Toronto Alexithymia Scale-20; CR: Cognitive Reappraisal; ES: Expressive Suppression; DIF: 
Difficulty in Identifying Feelings; DDF: Difficulty in Describing Feelings; POE: External Oriented 
Thinking 
Table 4 shows the correlations between clinical anamnestic data (i.e., number of drug reactions, 
time of reactions, severity of reactions, access to healthcare services) and emotional functioning 
(DERS, ERQ, and TAS-20 scores). Positive significant correlations between the time of 
reactions (0 = immediate, 1 = not immediate reactions) and DERS subscales (Non-Acceptance, 
Impulse, Strategy, DERS Total) in ADRs patients with nocebo effect are found (p values from 
.014 to .042). Furthermore, the access to healthcare services (0 = access, 1 = no access) is linked 
with Alexithymia total score (rpb = -.447, p = .013) and Expressive Suppression (rpb = .376, p = 
.040) in ADRs patients with nocebo effect. Conversely, data show a negative correlation 
between access to healthcare services and DERS Clarity in non responders (rpb = -.213, p = 
.045).  
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None correlations between the severity of reactions (0 = mild reactions, 1 = moderate-severe 
reactions) or the number of drug reactions (0 = one category, 1 = more than one category of 
drugs involved) and emotional functioning in both groups are found.  
Table 4. Point Biserial Correlations between clinical data and DERS, ERQ and TAS-20 scores 
in ADRs patients with nocebo effects and in no responders  
Number of  drug 
reactions 
Time of  reactions Severity of  reactions Access to healthcare services 
 Nocebo 
effect 
Non 
responders 
Nocebo 
effect 
Non 
responders 
Nocebo 
effect 
Non 
responders 
Nocebo 
effect 
Non 
responders 
NO ACCEPT. .060 -.122 .467* .031 .126 .106 -.079 -.143 
GOAL -.036 -.187 .219 .134 .107 .024 -.093 -.019 
IMPULSE .047 -.236 .507* -.029 .015 .146 .201 -.104 
AWAREN. .127 .053 .114 -.083 -.095 .111 .069 -.012 
STRATEGY .101 -.136 .428* .078 .080 .122 -.117 -.077 
CLARITY -.014 -.102 .041 -.039 .013 -.113 .057 -.213* 
DERS Total .091 -.194 .470* .042 .069 .138 -.024 -.134 
CR .039 .123 -.097 .105 .198 .013 -.059 .177 
ES .272 -.085 -.047 -.068 -.104 .103 .376* .054 
DIF -.155 -.085 .310 .028 .094 -.047 -.298 -.057 
DDF -.264 -.270 .093 .048 .290 .093 -316 -.148 
POE -.319 -.138 .028 -.014 .317 .117 -.244 -.189 
TAS-20 Total -.290 -.066 .293 -023 .279 .077 -.447* -.062 
Note: NON ACC.: Non acceptance; AWAREN.: Awareness; CR: Cognitive Reappraisal; ES: Expressive 
Suppression; DIF: Difficulty in Identifying Feelings; DDF: Difficulty in Describing Feelings; POE: 
External Oriented Thinking 
Given the significant correlations found in patients with nocebo reactions, two separate logistic 
regressions have been carried out to test the prediction power of emotion regulation problems 
on some of the ADR clinical anamnestic features (i.e., time of reactions and access to healthcare 
service). The first logistic regression model (Table 5) in which time of reactions is used as a 
categorical variable (0 = immediate; 1 = not immediate) shows that Non-Acceptance, Impulse, 
Strategy, and DERS total do not significantly predict this variable. Conversely, the second 
logistic regression model (Table 6) in which the access of healthcare service is used as a 
categorical variable (0 = access; 1 = no access) shows that alexithymia (TAS-20 Total) and 
Expressive Suppression significantly predicted this variable. The summary model fit is 
significant and explains 35% of the variance.  
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Table 5. Logistic regression analyses in ADRs patients with nocebo effects with time of 
reactions as the dependent variable and emotional problems as potential predictors  
Variable  B 
 
SE B Wald df p 95% CI 
Constant  -14.73 10.38 2.01 1 .156  
Non 
acceptance 
.34 .031 1.23 1 .267 .77, 2.58 
Impulse .59 .49 1.41 1 .234 .68, 4.75 
Strategy  -.50 .59 .72 1 .396 .19, 1.93 
DERS Total .10 .17 .38 1 .539 .79, 1.55 
Table 6. Logistic regression analyses in ADRs patients with nocebo effects with healthcare 
service access as the dependent variable and emotional problems as potential predictors  
Variable  B 
 
SE B Wald df p 95% CI 
Constant 9.46 4.69 4.06 1 .044*  
TAS-20 Total -.12 .05 5.70 1 .017* 1.03, 1.59 
ES .24 .11 4.79 1 .029* .81, .98 
 
4. Discussion 
The present study expands the knowledge on the psychological functioning of ADRs patients 
focusing on the nocebo reactions considering the paucity of studies on this topic. Starting from 
the assumptions whereby emotional problems are common in patients with multiple drug 
intolerance (De Pasquale et al., 2012; Patriarca et al., 1991) and a general deficit to regulate 
emotions connecting with physical sensations may worsen the outcome of the patients (Colloca 
& Benedetti, 2007; Rief et al., 2008), it is hypothesized to find emotional problems mainly in 
ADRs patients with nocebo reactions. Nevertheless, the first researchers’ hypothesis is not 
confirmed. Conversely to Patriarca et al. (1991), findings do not confirm a higher tendency to 
suppress emotions in ADR patients with nocebo effects than non responders. In contrast, they 
differ for a higher level of Cognitive Reappraisal, an adaptive strategy that involves reconsidering 
a stressful situation from a different perspective, producing a positive interpretation of the 
situation to decrease distress (Gross, 1998). Although the effect of age is influential in this 
finding and could be related to more adverse reactions in older patients, emotion regulation 
problems cannot be considered a central feature of nocebo effects. The study of Webb (2012) 
can help to understand this datum.  
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Each emotion regulation strategy, rather than being inherently adaptive or maladaptive, can be 
adaptive or maladaptive in a different context or depending on different situational 
contingencies.  
Besides, in contrast to De Pasquale et al. (2012) and other studies focused on other allergic 
diseases (Baiardini et al., 2011, 2015), the presence of higher difficulties identifying feelings, 
communicating feelings to other people and externally oriented thinking is not confirmed in 
this study. Nevertheless, a possible explanation of this datum is that the negative expectation of 
patients with ADRs may be more powerful and exceeds the conscious mind, moving beyond 
the emotional awareness and involving neurological markers as showed by researchers 
(Benedetti et al., 2007; Colloca & Miller, 2011; Lombardi et al., 2008). Finally, it is worth to note 
that patients analyzed by Patriarca and De Pasquale represent a particular subset of ADR 
patients, probably very different from the majority of patients considered in this study.  
Considering the second objective on the role of emotional problems as a central feature of 
clinical outcome (Aldao et al., 2010; Balzarotti et al., 2016; Gross & John, 2003), a link between 
emotional problems and clinical anamnestic features of ADRs patients with nocebo effect has 
been found. More concretely, higher levels of emotion dysregulation are linked with not 
immediate drug reactions, while higher levels of alexithymia and Expressive Suppression are 
linked with more frequent access to healthcare services. This can be argued that a lack of 
acceptance of emotions, an inability to refrain from impulsive behavior when experiencing 
negative emotions, and a lack to access to emotion regulation strategies perceived as effective 
(Gratz & Roemer, 2004) makes the ADRs patients with nocebo effect more vulnerable to show 
late-onset drug reactions. Besides, the inhibition of emotion regulation strategies as well as 
alexithymic features makes the patients with nocebo reactions more inclined to access the 
healthcare service. In other words, a primitive deficit in the emotions elaboration makes the 
patients most needy to care (Aldao et al., 2010; Lund et al., 2001; Subic-Wrana et al., 2010), 
providing recurrent hospitalizations, frequent requests for medical care and increasing their 
health costs. This underlines that the lack of expression of emotions leads to an evolution 
towards illness. Conversely, the number of drugs and the severity of reactions are not linked 
with emotional problems. The presence of a heterogeneous sample for clinical history including 
both participants with non-specific and mild reactions and participants with serious allergic 
reactions may explain this finding. 
Additionally, data from regression analyses add that if on the hand the dysregulation emotion 
features are not enough to predict the late-onset drug reaction, on the other hand, the inhibition 
of emotion regulation strategies as well as alexithymic features result as predictors of more 
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frequent access to healthcare services, evident in 35% of the sample. This suggests that different 
facets of emotional functioning have a different influence on the outcome. The knowledge of 
this can help the clinicians to promote a holistic comprehension of the disease (Cavanna, Bizzi, 
& Charpentier, 2015; Houlis, Cardinali, Cocchi, & Cavanna, 2019) and guide their behavior and 
reassurance communication enhancing the alliance of these patients (Planés, Villier, & Mallaret, 
2016).  
This study has several limitations. First, our sample size was quite small and not completely 
homogeneous. Studies using larger sample sizes are needed before firm conclusions can be 
drawn. Secondly, our study is a cross-sectional study we cannot make any causal inferences 
about the associations found between emotion regulation, alexithymia, and nocebo effect in 
ADRs patients. Thirdly, we only used self-report to evaluate emotional functioning. Future 
research should adopt a multi-method approach. Fourthly, an evaluation of the personality of 
these patients was missing, a methodological limitation that restricts the generalisability of our 
results.  
 
5. Conclusion 
Notwithstanding the limitations of this study, the current findings make a significant 
contribution to the knowledge of emotional functioning in ADRs patients with a focus on the 
nocebo phenomenon. Even if the role of emotions does not characterize ADRs patients with 
nocebo effect differently to non responders, a general deficit in the emotion regulation process 
connotes some of the clinical anamnestic features of these patients. Particular interesting 
appears to be the consequence of a dysfunctional relationship with the health services. The 
knowledge of this permits to better understand the nocebo phenomenon and consequently to 
increase insight on the management of these patients. Methods of limiting or reducing the 
nocebo effects must include optimal clinical-patient interactions to facilitate the emotional 
adjustment and promote psychological support shaping patients’ expectations and enhancing 
the treatment alliance to limit the typical nonadherence and the treatment discontinuity of these 
patients (Berrino et al., 2005; Colloca & Miller, 2011; Planés et al., 2016). In this way, it is 
important to establish a multidisciplinary working team aimed diagnose and correctly treat these 
patients, including a psychological intervention (Bizzi, Sciarretta, D’Alessandro, & Picco, 2016) 
and encouraging professionals to support their involvement into the management of the 
patients (Cardinali, Migliorini, & Rania, 2019).  
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